Nuhad K. Ibrahim

Nuhad K. Ibrahim is a Professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, where he specializes in breast oncology, cancer therapeutics, and translational pharmacology. His research focuses on developing novel treatment strategies for triple-negative breast cancer (TNBC), including neoadjuvant immunotherapy combinations, antibody-drug conjugates, and targeted therapies for chemotherapy-resistant disease. His recent work investigates immune correlates of pathological response to pembrolizumab-based regimens, the impact of ionizing radiation on cellular immunity in brain metastases, and biomarker-driven approaches using agents such as sacituzumab govitecan, tinengotinib, and eftilagimod alpha. He has contributed to multiple phase I/II clinical trials and first-in-human studies, advancing personalized adoptive cell therapy and precision oncology. His publications appear in Clinical Cancer Research, and he is recognized for his leadership in high-risk early-stage and metastatic breast cancer research.